Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (31308)	4/24/2003 2:06:36 PM
From: fred hayes	Read Replies (1) \| Respond to of 32384

>>There are still no real signs that sales of the oncology products are picking up. Especially Targretin in disappointing.<< Yup, sales numbers are disappointing on their face. But they may not be the whole story. LGND's press release indicates that "...prescriptions for Targretin capsules increased 34% compared to the same period of 2002...". Strange -- first Q 2002 showed $4.0 vs. $3.0 in 2003. Let's hope that usage is increasing based on the prescription info, and that the sales figures are misleading due to whatever (probably channel issues?). Or maybe I'm too optimistic... fred